Chih-Chang Wei
Research Subjects
Chih-Chang Wei has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dong Gao
Physician, First School of Clinical Medicine, Nanjing University of Chinese Medicine, and Department of Cardiovascular, Haimen Branch of Shanghai First People's Hospital Haimen Traditional Chinese Medicine Hospital, China. Conception and design of the study, manuscript writing
1 shared publication - Li Wang
Affiliated Mental Health Centre & Hangzhou Seventh People’s Hospital, Zhejiang University School of Medicine , Hangzhou
1 shared publication Wanmin Wang
Dalian Jinma Medical Technology Co., Ltd., Dalian, 116620, China
1 shared publicationXiaoling Luo
Shenzhen Hornetcorn Biotechnology Co., Ltd., Shenzhen, 518045, China
1 shared publicationYongguang Cai
The Fifth District of Chemotherapy, Department of Medical Oncology, Central Hospital of Guangdong Provincial Agricultural Reclamation, Zhanjiang, 524002, China
1 shared publication- Yuhuan Wang
Department of Gastroenterology, Children’s Hospital of Fudan University, National Children’s Medical Center, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (16) , 3183-3189
Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
Chemo- and radio-therapy suffer from certain well-recognized drawbacks for lymphoma therapy. Passive immunotherapy with monoclonal antibody has improved outcome for patients with CD20+ B cell lymphoma, but not for T cell lymphoma. Therefore, novel treatment approaches are clearly required for T cell lymphoma. To date, the combined application targeting TLR7, 8 and 9 has established long-term antitumor immunity. We previously synthesized a purine-scaffold TLR7 agonist named GD5. Here, we report that the intratumoral administration of GD5 combined with doxorubicin (DOX), a conventional chemotherapeutic agent in T cell lymphoma. This combined treatment made mice to produce more cytokines in blood, and generate more potent cytotoxic T lymphocyte response, then result in effective eradication of both local and distant tumors in tumor-bearing mice. Our findings demonstrate the potential for enhancing the efficacy of the current standard DOX therapy through combination with TLR7 agonist GD5 to improve antitumor immune responses and provide durable remissions for T cell lymphoma.
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (16) , 3183-3189
Open AccessSynergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
Chemo- and radio-therapy suffer from certain well-recognized drawbacks for lymphoma therapy. Passive immunotherapy with monoclonal antibody has improved outcome for patients with CD20+ B cell lymphoma, but not for T cell lymphoma. Therefore, novel treatment approaches are clearly required for T cell lymphoma. To date, the combined application targeting TLR7, 8 and 9 has established long-term antitumor immunity. We previously synthesized a purine-scaffold TLR7 agonist named GD5. Here, we report that the intratumoral administration of GD5 combined with doxorubicin (DOX), a conventional chemotherapeutic agent in T cell lymphoma. This combined treatment made mice to produce more cytokines in blood, and generate more potent cytotoxic T lymphocyte response, then result in effective eradication of both local and distant tumors in tumor-bearing mice. Our findings demonstrate the potential for enhancing the efficacy of the current standard DOX therapy through combination with TLR7 agonist GD5 to improve antitumor immune responses and provide durable remissions for T cell lymphoma.